HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

P&G Enters FY 2017 With Pressure To Execute In Line With Promises

This article was originally published in The Rose Sheet

Executive Summary

Increased R&D and ad spending, improved consumer communications and other brand-building investments will enable P&G to grow and recapture market share in fiscal 2017, company leadership suggests. While the stage may be set for P&G to “get the belt back,” as one analyst suggests, all are watching for execution.

You may also be interested in...



People In Brief: New Leadership For Lauder Brands; P&G Beauty Head Moves To Fashion; More

The Estee Lauder Companies, Procter & Gamble, Avon Products and Markwins announce changes to their executive management ranks, and Liz Earle says she will be leaving the natural-oriented brand she co-founded in 1995.

P&G Refocusing Olay Innovation As Brand Revival Continues

P&G leadership discussed the firm’s ongoing efforts to reinvigorate Olay, the only major brand in its skin and personal-care segment that has not grown over the past four years, during a Nov. 18 Analyst Day presentation.

Coty Wraps P&G Merger, Projects Return To Growth In FY 2017 Back Half

New CEO Camillo Pane says the 40-plus beauty brands picked up from P&G position Coty as a “challenger” in global beauty. The firm aims to achieve a “best-in-class profit margin and cash flow conversion model,” with projected growth acceleration in the second half of fiscal 2017.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS108488

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel